Michael Rosenzweig

USPTO Granted Patents = 22 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 12 (Patent Applications = 11)

Average Co-Inventor Count = 3.9

ph-index = 12

Forward Citations = 653(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

8. 1 out of 832,680

Other

patents

Years Active: 1997-2021

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11052065 - Compositions and methods for treating cancer with a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist (2021-07-06),

2. 10570209 - Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies (2020-02-25),

3. 10370455 - Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists (2019-08-06),

4. 10030074 - Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies (2018-07-24),

5. 9828425 - Anti-ILT5 antibodies and ILT5-binding antibody fragments (2017-11-28),

6. 9534051 - Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments (2017-01-03),

7. 9493572 - GITR antibodies and methods of inducing or enhancing an immune response (2016-11-15),

8. 9241992 - Combination therapies employing GITR binding molecules (2016-01-26),

9. 9028823 - Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies (2015-05-12),

10. 9023997 - Anti-ILT5 antibodies and ILT5-binding antibody fragments (2015-05-05),

11. 8901281 - ILT3 binding molecules and uses therefor (2014-12-02),

12. 8846397 - Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments (2014-09-30),

13. 8591886 - Combination therapies employing GITR binding molecules (2013-11-26),

14. 8388967 - Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies (2013-03-05),

15. 7812135 - GITR-binding antibodies (2010-10-12),

Title: **Innovations by Michael Rosenzweig: Pioneering Cancer Treatments**

Introduction

Michael Rosenzweig is a prominent inventor based in Boston, MA, known for his significant contributions to the field of cancer treatment. With a remarkable portfolio of 22 patents, he has developed innovative therapies aimed at improving patient outcomes in oncology. His research focuses on enhancing immune responses and the effective treatment of cell proliferation disorders.

Latest Patents

Among Rosenzweig's latest patents is a groundbreaking method for treating cancer using a combination of programmed death receptor (PD-1) antibodies and a CXCR2 antagonist. This invention outlines a comprehensive approach to treating various cancer types by administering specific compounds to patients in need.

Additionally, his patent on methods for inducing or enhancing an immune response utilizes agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies. This invention particularly emphasizes the ability of binding molecules to interact with human GITR on T cells and dendritic cells, thus facilitating an improved immune response against tumors. The pharmaceutical compositions and kits developed from this research represent significant advancements in therapeutic strategies for cancer treatment.

Career Highlights

Throughout his career, Michael Rosenzweig has worked with renowned organizations, including Gitr, Inc. and Merck Sharp & Dohme Corporation. His experiences in these companies have enriched his expertise in biopharmaceutical innovation, particularly in the development of cancer therapies.

Collaborations

Rosenzweig has collaborated with esteemed colleagues such as Paul D Ponath and Jose F Ponte, contributing to projects that aim to advance the understanding and treatment of cancer. These collaborations have synergized their collective expertise to accelerate the development of novel therapeutic strategies.

Conclusion

Michael Rosenzweig's work continues to impact the landscape of cancer treatment significantly. Through his patents and collaborative efforts, he is helping to pave the way for innovative therapeutic approaches that can lead to better patient outcomes and advancements in medical science. His dedication to this critical field underlines the importance of continuous innovation and research in combating cancer.

This text is generated by artificial intelligence and may not be accurate.